Rick opens this one with an image he couldn't shake after a trip to Denmark: you could take a two-ton block of marble and hammer 25% of the weight off it, and you'd still have a block. It looks like nothing. That, he argues, is what crash dieting does — and the actual goal is to pick away gently and intentionally at what you don't want while keeping the form that's already inside the stone.

From there, Rick and Greg build out the one-key, two-key, three-key model of GLP-1 medications. Every one of these drugs is a copycat key that fits a lock your body already has. Semaglutide turns one key, opening receptors in the brain that quiet food noise, in the stomach that slow gastric emptying, and in the pancreas that time insulin release to actual glucose spikes — with the tradeoff being nausea and GI side effects. Tirzepatide turns two, adding the GIP lock that calms the brain's nausea center and helps fat cells store fat where it belongs instead of tucking it into the liver and muscles, like dirty socks stuffed under the couch cushions. And retatrutide — still in trials, not approved, and the subject of some candid commentary here about Eli Lilly's biologic-classification maneuvering — turns three, adding glucagon to burn liver fat and nudge resting metabolic rate upward.

The numbers tell the arc: roughly 15% body weight on semaglutide, 21% on tirzepatide, and 28–30% in early retatrutide trials. But Rick and Greg keep circling back to the marble. Losing a hundred pounds the right way isn't chipping the block. It's chiseling the Michelangelo.

Educational and informational only. GLP-1 medications require a prescription and medical supervision. Retatrutide is not FDA approved and is not legally available. Talk with your healthcare provider before starting any medication, supplement, or weight loss program.